References
- 1. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004; 363:1377-85.10.1016/S0140-6736(04)16051-0
- 2. Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000; 26:581-9.10.1016/S8756-3282(00)00269-6
- 3. Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab. 2006; 91:511-6.10.1210/jc.2005-2036
- 4. Vallo A, Rodriguez-Leyva F, Rodriguez Soriano J. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy. Acta Paediatr. 2006; 95:332-9.10.1080/08035250500434785
- 5. Brown JJ, Zacharin MR. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab. 2009; 22:55-63.10.1515/JPEM.2009.22.1.55
- 6. Marini JC. Bone: Use of bisphosphonates in childrenproceed with caution. Nat Rev Endocrinol. 2009; 5: 241-3.10.1038/nrendo.2009.58
- 7. Zittermann A. Effects of vitamin K on calcium and bone metabolism. Curr Opin Clin Nutr Metab Care. 2001; 4: 483-7.10.1097/00075197-200111000-00003
- 8. Kaneki M, Hosoi T, Ouchi Y, Orimo H. Pleiotropic actions of vitamin K: protector of bone health and beyond? Nutrition. 2006; 22:845-52.10.1016/j.nut.2006.05.003
- 9. Hodges SJ, Pilkington MJ, Stamp TC, Catterall A, Shearer MJ, Bitensky L, et al. Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. Bone. 1991; 12:387-9.10.1016/8756-3282(91)90027-G
- 10. Hodges SJ, Akesson K, Vergnaud P, Obrant K, Delmas PD. Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res. 1993; 8:1241-5.10.1002/jbmr.56500810128256661
- 11. Tamatani M, Morimoto S, Nakajima M, Fukuo K, Onishi T, Kitano S, et al. Decreased circulating levels of vitamin K and 25-hydroxyvitamin D in osteopenic elderly men. Metabolism. 1998; 47:195-9.10.1016/S0026-0495(98)90220-7
- 12. Booth SL, Broe KE, Peterson JW, Cheng DM, Dawson- Hughes B, Gundberg CM, et al. Associations between vitamin K biochemical measures and bone mineral density in men and women. J Clin Endocrinol Metab. 2004; 89:4904-9.10.1210/jc.2003-03167315472183
- 13. Hauschka PV, Lian JB, Gallop PM. Direct identification of the calcium-binding amino acid, gammacarboxyglutamate, in mineralized tissue. Proc Natl Acad Sci USA. 1975; 72:3925-9.10.1073/pnas.72.10.39254331091060074
- 14. Price PA, Otsuka AA, Poser JW, Kristaponis J, Raman N. Characterization of a gamma-carboxyglutamic acidcontaining protein from bone. Proc Natl Acad Sci USA. 1976; 73:1447-51.10.1073/pnas.73.5.14474303131064018
- 15. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res. 2000; 15:515-21.10.1359/jbmr.2000.15.3.51510750566
- 16. Bunyaratavej N, Penkitti P, Kittimanon N, Boonsangsom P, Bonjongsat A, Yunoi S. Efficacy and safety of Menatetrenone-4 postmenopausal Thai women. J Med Assoc Thai. 2001; 84 Suppl 2:S553-9.
- 17. Iwamoto J, Takeda T, Ichimura S. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. J Orthop Sci. 2001; 6:487-92.10.1007/s00776010000211793169
- 18. Inoue T, Fujita T, Kishimoto H, Makino T, Nakamura T, Nakamura T, et al. Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. J Bone Miner Metab. 2009; 27:66-75.10.1007/s00774-008-0008-819082528
- 19. Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina- Granade G, Duboeuf F, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res. 2006; 21:300-6.10.1359/JBMR.05101516418786